Resurrection of Biogen’s and Eisai’s Aducanumab?
Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation jcm9144@gmail.com
SPECIAL REPORT #35
Resurrection of Biogen’s and Eisai’s Aducanumab?
Earlier this week, Biogen and partner Eisai have announced that they will file a Biologics License Agreement (BLA) at the US FDA, early next year, for aducanamab, an amyloid-targeting monoclonal antibody, as a new treatment for Alzheimer’s disease. The announcement comes as a major surprise to all analysts, just months after both companies had indicated that the development of the drug had been stopped after the failure of a futility analysis. In a note titled “Shocking, simply shocking”, J.P. Morgan’s analyst Corey Kasimob wrote “We are left somehow speechless by news this morning that Biogen’s Alzheimer’s drug candidate aducanumab is back from the dead”. In making its case, Biogen argued that the futility analysis was based on a smaller data set that featured fewer patients who received a high-dose of aducanumab. Adding the additional data, aducanumab showed statistically significant changes on clinical dementia scale with the highest dose and still supports the validity of the anti-amyloid hypothesis. “The result of the futility was incorrect” wrote Biogen in a presentation where it shared some of the evidence it had gathered in the expanded data set for one of the phase 3 trials EMERGE. We do not consider ourselves as sufficiently expert in the field to make a relevant assessment on our own and explain the better results seen in the various subsets of ENGAGE patients and the EMERGE trials. Many analysts are now very eager to see how the US FDA will handle the aducanumab case. Will there be the call of an advisory board? Will the FDA, possibly with a new Commissioner, approve a new medicine based on some unconventional evidence falling short of usual standards, because the drug targets a major unmet medical need?
Biogen shares rose by 30% just after the announcement. Adacunamab is now valued at 0 or $12 billion and has the potential to complete change the profile of the company.
October 27, 2019
This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.
Last News
- Alzheimer’s disease : Beyond the beta amyloid hypothesis
- Un monde posteuropéen : déjà une réalité ?
- PIB, Budget, Dépenses : Une mise au point.
Events
News archives
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- March 2024
- February 2024
- January 2024
- November 2023
- September 2023
- July 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- October 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- November 2013
- September 2013
- July 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- March 2012